Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure
Terminated
H. Lundbeck A/S
N/A
2009-01-01
The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early
vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a
higher PDA closure rate than later use of Ibu. Early use is defined as medication given
before the infant reaches 96 hrs old. Late use is defined as medication given when infant is
more than 96 hrs old.
Early Versus Late Use of Ibuprofen for Patent Ductus Arteriosus (PDA) Closure
Terminated
University of Utah
N/A
2009-01-01
The primary objective is to evaluate the Patent Ductus Arteriosus (PDA) closure rate of early
vs. late use of Ibuprofen (Ibu). The investigators believe that early use of Ibu will have a
higher PDA closure rate than later use of Ibu. Early use is defined as medication given
before the infant reaches 96 hrs old. Late use is defined as medication given when infant is
more than 96 hrs old.
Safety/Efficacy Study of Optimizing Ibuprofen Dosing to Achieve Higher PDA Closure Rates
Terminated
OSF Healthcare System
Phase 4
2009-08-01
The purpose of this study is to determine if increasing the ibuprofen dose will increase the
likelihood of closing the patent ductus arteriosus in premature babies.
Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic
Completed
Maricopa Integrated Health System
N/A
2014-09-09
The aim of this study is to assess the analgesic efficacy of intravenous ibuprofen given in
the Emergency Department for the treatment of biliary colic. We hypothesize that intravenous
ibuprofen will provide a clinically significant drop in self-reported patient pain level as
measured by the visual analog scale.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
